BDTX (Black Diamond Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)

What is Black Diamond Therapeutics FCF Margin %?

Black Diamond Therapeutics BDTX +0.59% 38 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Black Diamond Therapeutics ranks better than 54.54% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Black Diamond Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-10.23 Mil. Black Diamond Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Black Diamond Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Black Diamond Therapeutics's current FCF Yield % is -34.73%.

The historical rank and industry rank for Black Diamond Therapeutics's FCF Margin % or its related term are showing as below:

BDTX' s FCF Margin % Range Over the Past 10 Years
Min: -48.61 Med: 42.31 Max: 42.31
Current: -48.61

During the past 9 years, the highest FCF Margin % of Black Diamond Therapeutics was 42.31%. The lowest was -48.61%. And the median was 42.31%.

BDTX's FCF Margin % is ranked better than
54.54% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs BDTX: -48.61

Black Diamond Therapeutics FCF Margin % Related Terms

Black Diamond Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics FCF Margin % Chart

Black Diamond Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

0.00

42.31

Black Diamond Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															76.30	0.00	0.00	0.00	0.00

BDTX vs GUTS, ALPS, ONCY: FCF Margin % Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's FCF Margin % falls into.

Save Embed

38GF Score

Black Diamond Therapeutics Inc BDTX

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Black Diamond Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Black Diamond Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	29.614	/	70
	=	42.31 %

Black Diamond Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-10.232	/	0
	=	%

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 0.00% mean?

Black Diamond Therapeutics (BDTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Black Diamond Therapeutics and its competitors. According to the industry distribution chart, Black Diamond Therapeutics ranks #436 out of 959 companies in the Biotechnology industry, placing it in the top 45.5%.

Is Black Diamond Therapeutics' FCF Margin % too high?

Black Diamond Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Black Diamond Therapeutics ranks #436 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Black Diamond Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.

How does Black Diamond Therapeutics' FCF Margin % compare to GUTS and ALPS?

According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #436 out of 959 companies for FCF Margin %. This puts Black Diamond Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Black Diamond Therapeutics stock overvalued right now?

Black Diamond Therapeutics (BDTX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Black Diamond Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies GUTS ALPS ONCY CRDF KLRS ENGN VTVT NTHI ACOG GNLX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142

Website https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

38GF Score

Get the complete analysis for BDTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71

Price

View BDTX Analysis

See FCF Margin % data for all stocks →